Metallization by Sputtering to Improve the Bond Strength between Zirconia Ceramics and Resin Cements.

Zirconia has been used as a prosthesis material for over a decade because of its excellent mechanical properties and esthetics. The surface treatment for zirconia generally involves sandblasting and the application of primers for favorable bond strength between the surface and resin. However, sandblasting causes the microcracking and chipping of the zirconia surface.

Effect of pre-coating with methyl methacrylate containing UV photoinitiators on the bond strength of poly(ether ether ketone).

This study investigates the effect of pre-coating with methyl methacrylate (MMA) containing ultraviolet (UV) photoinitiators on the bond strength of poly(ether ether ketone) (PEEK). Cylindrical PEEK blocks were irradiated with 365 nm UV light for 5-20 s after they were coated with MMA containing 0.4-3.

Sulfated vizantin induces formation of macrophage extracellular traps.

Vizantin is an insoluble adjuvant that activates macrophages and lymphocytes. Recently, 2,2',3,3',4,4'-hexasulfated-vizantin (sulfated vizantin), which enables solubilization of vizantin, was developed by the present team. Sulfated vizantin was found to enhance bactericidal activity against multi-drug resistant Pseudomonas aeruginosa in RAW264.

A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia.

Objective: The objective of this study was to evaluate the short-term efficacy and safety of the atypical antipsychotic agent lurasidone in the treatment of schizophrenia.

Methods: In this phase II, randomized, double-blind, placebo-controlled study, hospitalized adult patients diagnosed with schizophrenia and experiencing an acute exacerbation of psychotic symptoms were randomly assigned to 6 weeks of fixed-dose lurasidone 20 mg/day (n = 71), lurasidone 40 mg/day (n = 67), lurasidone 80 mg/day (n = 71), haloperidol 10 mg/day (n = 72, included to test for assay sensitivity), or placebo (n = 72). Efficacy was assessed using the brief psychiatric rating scale, positive and negative syndrome scale, and clinical global impression-severity.

Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study.

Rationale: There is an unmet need in the treatment of schizophrenia for effective medications with fewer adverse effects.

Objective: This study aims to evaluate the efficacy and safety of lurasidone, an atypical antipsychotic, for the treatment of schizophrenia.

Methods: Patients with an acute exacerbation of schizophrenia were randomized to 6 weeks of double-blind treatment with once-daily, fixed-dose lurasidone 40 mg (N = 50), lurasidone 120 mg (N = 49), or placebo (N = 50).